Dose verification of intensity modulated radiotherapy in head and neck tumors
Purpose: To evaluate the agreement between measured and calculated doses for head and neck tumors using different gamma criteria and to establish quality assurance protocol for the delivery of IMRT in The National Cancer Institute in Cairo.
Methods: The dose is calculated for 30 patients using CMS Treatment Planning System. The ionization chamber (0.6 cm3 Farmer type) is used for point dose measurements. The 2D-array (PTW 729) and GafChromic films (EBT2) are used for 2D graphical dose distribution. Four different gamma criteria of dose difference (DD) and distance to agreement (DTA) (3%/3 mm, 3%/5 mm, 4%/4 mm and 5%/5 mm DD / DTA) are selected. These criteria are evaluated while suppressing the dose of 10%, 20% or 30% from dose distribution.
Results: Point dose evaluations using the ion chamber ranged from -2.6% to 3.7% (mean and standard deviation of 0.46 ± 1.7). Significant differences are observed between the films and 2D-array for all criteria except the 3%/5 mm criteria (96.89 ± 2.2% vs. 94.81 ± 4.2% (p < 0.01)).
Conclusion: Differences may exceed about 3% when the ionization chamber is present in steep dose gradient regions. The present results suggest the gamma criteria of 3%/5 mm as the most suitable criteria for IMRT quality assurance. This gamma criterion of 3%/5 mm favorably exceeds 95% in case of maximum dose while suppressing the dose of 20%.The use of 2D-array can reduce the IMRT QA workload.
Cite this article as: Elawady RA, Attalla EM, Elshemey WM, Shouman T, Alsayed AA. Dose verification of intensity modulated radiotherapy in head and neck tumors. Int J Cancer Ther Oncol 2014; 2(3):02037. DOI: 10.14319/ijcto.0203.7
Ezzel G A, Galvin J M, Low D, et al. Guidance document on delivery, treatment planning, and clinical implementation of IMRT: report of the IMRT Subcommittee of the AAPM Radiation Therapy Committee. MedPhys 2003; 30:2089 -115.
Anjum MN1, Parker W, Ruo R, Afzal M. Evaluation criteria for film based intensity modulated radiation therapy quality assurance. Phys Med 2010; 26:38-43.
Burman C, Chui CS, Kutcher G, et al. Planning, delivery, and quality assurance of intensity-modulated radiotherapy using dynamic multileaf collimator: a strategy for large-scale implementation for the treatment of carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1997; 39: 863-73.
Kron T, Hamilton C, Roff M, Denham J. Dosimetric intercomparison for two Australasian clinical trials using an anthropomorphic phantom. Int J Radiat Oncol Biol Phys 2002; 52:566-79.
Dong L, Antolak J, Salehpour M, et al. Patient-specific point dose measurement for IMRT monitor unit verification. Int J Radiat Oncol Biol Phys 2003; 56: 867-77.
Low DA and Dempsey JF. Evaluation of the gamma dose distribution comparison method. Med Phys 2003; 30:2455-64.
Childress NL, White RA, Bloch C, et al. Retrospective analysis of 2D patient-specific IMRT verifications. Med Phys 2005; 32:838-50.
Saminathan S, Manickam R, Chandraraj V, Supe S. Dosimetric study of 2D ion chamber array matrix for the modern radiotherapy treatment verification. J Appl Clin Med Phys 2010; 11:3076.
Eisbruch A, Ship JA, Martel MK, et al. Parotid gland sparing in patients undergoing bilateral head and neck irradiation: techniques and early results. Int J Radiat Oncol Biol Phys 1996; 36:469-80.
Ozyigit G, Yang T, Chao KS. Intensity-modulated radiation therapy for head and neck cancer. Curr Treat Options Oncol 2004; 5:3- 9.
ICRU Report 83, Prescribing, Recording, and Reporting Photon-Beam Intensity-Modulated Radiation Therapy (IMRT). Journal of the ICRU 2010; 10.
Low DA, Moran JM, Dempsey JF, et al. Dosimetry tools and techniques for IMRT. Med Phys 2011; 38: 1313-38.
Mijheer B, Georg D. Guidelines for the verification of IMRT. ESTRO BOOKLET NO. 9: Brussels, Belgium, 2008.
Agnew CE, Irvine DM, Hounsell AR, McGarry CK. Improvement in clinical step and shoot intensity modulated radiation therapy delivery accuracy on an integrated linear accelerator control system. Pract Radiat Oncol 2014; 4:43–9.
Syam Kumar SA, Sukumar P, Sriram P, et al. A patient-specific quality assurance study on absolute dose verification using ionization chambers of different volumes in RapidArc treatments. Med Dosim 2012; 37: 436-41.
Chung H, Li J, Samant S. Feasibility of using two-dimensional array dosimeter for in vivo dose reconstruction via transit dosimetry. J Appl Clin Med Phys 2011; 12:3370.
Fenoglietto P, Laliberté B, Aillères N, et al. Eight years of IMRT quality assurance with ionization chambers and film dosimetry: experience of the Montpellier Comprehensive Cancer Center. Radiat Oncol 2011; 6:85.
Escudé L, Linero D, Mollà M, Maralbell R. Quality assurance for radiotherapy in prostate cancer: point dose measurements in intensity modulated fields with large dose gradients. Int JRadiat Oncol Biol Phys 2006; 66: S136-40.
Laub WU and Wong T. The volume effect of detectors in the dosimetry of small fields used in IMRT. Med Phys 2003; 30:341-347.
Sánchez-Doblado F, Hartmann GH, Pena J, et al. Uncertainty estimation in IMRT absolute dosimetry verification. Int J Radiat Oncol Biol Phys 2007; 68: 301-10.
Li Q, Li L, Han J, Liang Z. Dose distribution verifications of IMRT for NPC. J Huazhong Univ Sci Technolog Med Sci 2009; 29:673-6.
Day RA, Sankar AP, Nailon WH, MacLeod AS. On the use of computed radiography plates for quality assurance of intensity modulated radiation therapy dose distributions. Med Phys 2011; 38:632-45.
Zhang Y, Gao Y. Dosimetric verification of the intensity modulated radiation therapy. Zhongguo Yi Liao Qi Xie Za Zhi 2010; 34:218-20, 223.
Ahluwalia B, Saini DS. IMRT QA with 2-dimensional Diode Array of Detectors. Presented at ICMP and Silver Jubilee AMPI Conference, New Delhi, India October 2004. Available from: http://sunnuclear.com/Papers/MapCHECKPaper.pdf
Létourneau D, Gulam M, Yan D, et al. Evaluation of a 2D diode array for IMRT quality assurance. Radiother Oncol 2004; 70:199-206.
This work is licensed under a Creative Commons Attribution 3.0 License.
International Journal of Cancer Therapy and Oncology (ISSN 2330-4049)
© International Journal of Cancer Therapy and Oncology (IJCTO)
To make sure that you can receive messages from us, please add the 'ijcto.org' domain to your e-mail 'safe list'. If you do not receive e-mail in your 'inbox', check your 'bulk mail' or 'junk mail' folders.